Palladia/Losartan/Ladarixin Combination Therapy for Metastatic Osteosarcoma

Patient Disease:

Canine Osteosarcoma with Metastasis to the Lungs

Study Name:

Modulating the Tumor Microenvironment in Metastatic Osteosarcoma: Palladia/Losartan/Ladarixin Combination Therapy

Purpose of the study:

  • To investigate the safety and biologic activity of combined treatment with losartan, Palladia, and ladarixin in dogs with metastatic OS to the lungs, assess the overall response rate and duration of response to this treatment, and determine the effects of treatment on tumor genetics and the immune system

Primary Eligibility Criteria:

  • Dogs that have had surgery to remove their primary tumor and a confirmed diagnosis of osteosarcoma with measurable metastatic disease in the lungs on chest X-rays
  • Adequate blood work
  • No prior treatment for lung metastasis
  • No metastatic disease anywhere besides the lungs
  • Cannot have previously received immune-suppressive medications for any condition
  • Pets must come to CSU for all visits related to the clinical trial

Study Protocol:

  • Dogs will be treated with oral losartan and ladarixin to be given twice daily and oral Palladia given once every other day.
  • Rechecks will be required 2 and 4 weeks after starting treatment and every 4 weeks thereafter if tumors are stable or better
  • Chest x-rays will be rechecked every 4 weeks while on study

Owner Responsibilities:

  • You are responsible for the initial testing to determine study eligibility and any other tests recommended by your pet’s oncologist
  • You are expected to make and keep all appointments associated with the study
  • You must be comfortable administering oral medications at home

Financial Incentives:

  • All costs associated with the trial will be covered up to a total of $5,000
  • Toceranib, losartan, and ladarixin will be provided at no cost other than the pharmacy dispensing fee ($8 per prescription)
  • Up to $500 is available to treat side effects related to the study drugs
  • After the initial 6 months of the study, you are responsible for all costs related to study participation other than the medications

 


If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.

flint animal cancer center newsletter

join our community

Be among the first to learn the latest Flint Animal Cancer Center news and pet cancer treatment information.
  • This field is for validation purposes and should be left unchanged.